Kodiak Sciences FY2025 EPS Estimate Lowered by HC Wainwright

Kodiak Sciences Inc. (NASDAQ:KOD) – Research analysts at HC Wainwright dropped their FY2025 EPS estimates for shares of Kodiak Sciences in a research report issued on Monday, November 17th. HC Wainwright analyst M. Caufield now expects that the company will earn ($4.35) per share for the year, down from their previous forecast of ($4.10). HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.07) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.88) EPS, FY2027 earnings at ($3.07) EPS, FY2028 earnings at ($2.28) EPS and FY2029 earnings at ($0.82) EPS.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.09).

Several other research firms also recently issued reports on KOD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a report on Wednesday, October 8th. JPMorgan Chase & Co. upgraded Kodiak Sciences from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $15.00 to $24.00 in a report on Friday, October 24th. Chardan Capital reissued a “neutral” rating and set a $14.00 target price on shares of Kodiak Sciences in a report on Monday. Wall Street Zen lowered Kodiak Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 11th. Finally, Jefferies Financial Group assumed coverage on Kodiak Sciences in a research note on Monday, September 22nd. They issued a “buy” rating and a $15.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $22.67.

Kodiak Sciences Trading Down 3.1%

Shares of NASDAQ:KOD opened at $19.22 on Wednesday. The company has a market capitalization of $1.02 billion, a PE ratio of -4.67 and a beta of 2.88. Kodiak Sciences has a 12-month low of $1.92 and a 12-month high of $22.14. The business has a 50 day moving average of $15.53 and a two-hundred day moving average of $9.24.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KOD. Acadian Asset Management LLC raised its position in shares of Kodiak Sciences by 27.0% during the 1st quarter. Acadian Asset Management LLC now owns 1,946,134 shares of the company’s stock valued at $5,454,000 after buying an additional 413,821 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in Kodiak Sciences by 90.1% during the first quarter. Jacobs Levy Equity Management Inc. now owns 685,198 shares of the company’s stock worth $1,922,000 after acquiring an additional 324,722 shares during the last quarter. Nuveen LLC purchased a new stake in Kodiak Sciences in the first quarter valued at $392,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Kodiak Sciences by 16.3% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,325,707 shares of the company’s stock valued at $3,719,000 after purchasing an additional 186,180 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Kodiak Sciences during the 1st quarter worth $126,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.